Quince Therapeutics, Inc. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that Quince Therapeutics, Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($83.98M) | Apr 10, 2026 |
| FY2025 | Dec 31, 2024 | ($56.83M) | Apr 10, 2026 |
| FY2024 | Dec 31, 2023 | ($31.39M) | Mar 24, 2025 |
| FY2023 | Dec 31, 2022 | ($51.66M) | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | ($89.95M) | Mar 15, 2023 |
| FY2021 | Dec 31, 2020 | ($76.85M) | Mar 1, 2022 |
| FY2021 | Dec 31, 2019 | ($36.98M) | Mar 1, 2022 |
| FY2020 | Dec 31, 2018 | ($12.48M) | Mar 1, 2021 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($58.07M) | Apr 10, 2026 |
| FY2025 | Dec 31, 2024 | ($57.29M) | Apr 10, 2026 |
| FY2024 | Dec 31, 2023 | ($34.62M) | Mar 24, 2025 |
| FY2023 | Dec 31, 2022 | ($52.02M) | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | ($90.32M) | Mar 15, 2023 |
| FY2021 | Dec 31, 2020 | ($78.89M) | Mar 1, 2022 |
| FY2021 | Dec 31, 2019 | ($39.17M) | Mar 1, 2022 |
| FY2020 | Dec 31, 2018 | ($12.12M) | Mar 1, 2021 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $35.38M | Apr 10, 2026 |
| FY2025 | Dec 31, 2024 | $18.59M | Apr 10, 2026 |
| FY2024 | Dec 31, 2023 | $9.45M | Mar 24, 2025 |
| FY2023 | Dec 31, 2022 | $25.18M | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | $60.80M | Mar 15, 2023 |
| FY2021 | Dec 31, 2020 | $61.31M | Mar 1, 2022 |
| FY2021 | Dec 31, 2019 | $30.21M | Mar 1, 2022 |
| FY2020 | Dec 31, 2018 | $10.09M | Mar 1, 2021 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($41.43M) | Apr 10, 2026 |
| FY2025 | Dec 31, 2024 | ($31.90M) | Apr 10, 2026 |
| FY2024 | Dec 31, 2023 | ($18.29M) | Mar 24, 2025 |
| FY2023 | Dec 31, 2022 | ($44.04M) | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | ($62.93M) | Mar 15, 2023 |
| FY2021 | Dec 31, 2020 | ($50.82M) | Mar 1, 2022 |
| FY2021 | Dec 31, 2019 | ($33.28M) | Mar 1, 2022 |
| FY2020 | Dec 31, 2018 | ($11.70M) | Mar 1, 2021 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $352.0K | Apr 10, 2026 |
| FY2025 | Dec 31, 2024 | $257.0K | Apr 10, 2026 |
| FY2024 | Dec 31, 2023 | $160.0K | Mar 24, 2025 |
| FY2023 | Dec 31, 2022 | $133.0K | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | $180.0K | Mar 15, 2023 |
| FY2021 | Dec 31, 2020 | $52.0K | Mar 1, 2022 |
| FY2021 | Dec 31, 2019 | $55.0K | Mar 1, 2022 |
| FY2020 | Dec 31, 2018 | $212.0K | Mar 1, 2021 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $93.52M | Apr 10, 2026 |
| FY2025 | Dec 31, 2024 | $114.48M | Apr 10, 2026 |
| FY2024 | Dec 31, 2023 | $167.90M | Mar 24, 2025 |
| FY2023 | Dec 31, 2022 | $103.91M | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | $133.23M | Mar 15, 2023 |
| FY2021 | Dec 31, 2020 | $189.47M | Mar 1, 2022 |
| FY2020 | Dec 31, 2019 | $124.37M | Mar 1, 2021 |
| FY2019 | Dec 31, 2018 | $72.88M | Mar 16, 2020 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $129.24M | Apr 10, 2026 |
| FY2025 | Dec 31, 2024 | $84.33M | Apr 10, 2026 |
| FY2024 | Dec 31, 2023 | $82.82M | Mar 24, 2025 |
| FY2023 | Dec 31, 2022 | $3.32M | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | $14.64M | Mar 15, 2023 |
| FY2021 | Dec 31, 2020 | $17.20M | Mar 1, 2022 |
| FY2020 | Dec 31, 2019 | $8.89M | Mar 1, 2021 |
| FY2019 | Dec 31, 2018 | $1.46M | Mar 16, 2020 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($35.71M) | Apr 10, 2026 |
| FY2025 | Dec 31, 2024 | $30.15M | Apr 10, 2026 |
| FY2025 | Dec 31, 2023 | $85.08M | Apr 10, 2026 |
| FY2024 | Dec 31, 2022 | $100.59M | Mar 24, 2025 |
| FY2023 | Dec 31, 2021 | $118.59M | Apr 1, 2024 |
| FY2022 | Dec 31, 2020 | $172.26M | Mar 15, 2023 |
| FY2021 | Dec 31, 2019 | $115.48M | Mar 1, 2022 |
| FY2021 | Dec 31, 2018 | ($32.63M) | Mar 1, 2022 |
| FY2020 | Dec 31, 2017 | ($20.28M) | Mar 1, 2021 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2024 | $0 | Apr 10, 2026 |
| FY2025 | Dec 31, 2023 | $17.63M | Apr 10, 2026 |
| FY2024 | Dec 31, 2022 | $0 | Mar 24, 2025 |
| FY2023 | May 19, 2022 | $825.0K | Apr 1, 2024 |
| FY2023 | Dec 31, 2021 | $0 | Apr 1, 2024 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($460.45M) | Apr 10, 2026 |
| FY2025 | Dec 31, 2024 | ($376.47M) | Apr 10, 2026 |
| FY2024 | Dec 31, 2023 | ($319.64M) | Mar 24, 2025 |
| FY2023 | Dec 31, 2022 | ($288.26M) | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | ($236.60M) | Mar 15, 2023 |
| FY2021 | Dec 31, 2020 | ($146.65M) | Mar 1, 2022 |
| FY2020 | Dec 31, 2019 | ($69.81M) | Mar 1, 2021 |
| FY2019 | Dec 31, 2018 | ($32.83M) | Mar 16, 2020 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $5.81M | Apr 10, 2026 |
| FY2025 | Dec 31, 2024 | $6.21M | Apr 10, 2026 |
| FY2019 | Dec 31, 2019 | $51.21M | Mar 16, 2020 |
| FY2019 | Dec 31, 2018 | $24.87M | Mar 16, 2020 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $0 | Apr 10, 2026 |
| FY2025 | Dec 31, 2024 | $14.32M | Apr 10, 2026 |
| FY2024 | Dec 31, 2023 | $13.43M | Mar 24, 2025 |
| FY2023 | Dec 31, 2022 | $0 | Apr 1, 2024 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (1) | Apr 10, 2026 |
| FY2025 | Dec 31, 2024 | (1) | Apr 10, 2026 |
| FY2024 | Dec 31, 2023 | 0 | Mar 24, 2025 |
| FY2023 | Dec 31, 2022 | (1) | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | (3) | Mar 15, 2023 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (1) | Apr 10, 2026 |
| FY2025 | Dec 31, 2024 | (1) | Apr 10, 2026 |
| FY2024 | Dec 31, 2023 | 0 | Mar 24, 2025 |
| FY2023 | Dec 31, 2022 | (1) | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | (3) | Mar 15, 2023 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 55.73M | Apr 10, 2026 |
| FY2025 | Dec 31, 2024 | 44.00M | Apr 10, 2026 |
| FY2024 | Dec 31, 2023 | 42.97M | Mar 24, 2025 |
| FY2023 | Dec 31, 2022 | 36.14M | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | 30.07M | Mar 15, 2023 |
| FY2021 | Dec 31, 2020 | 29.54M | Mar 1, 2022 |
| FY2020 | Dec 31, 2019 | 26.87M | Mar 1, 2021 |
| FY2019 | Dec 31, 2018 | 3.41M | Mar 16, 2020 |